Linked Life Data

1710485

Source:http://linkedlifedata.com/resource/pubmed/id/1710485

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1991-7-17
pubmed:abstractText
Between 1981 and 1986, 126 patients with diffuse large cell lymphoma were treated with MACOP-B (methotrexate/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomy cin). All had advanced-stage lymphoma (Ann Arbor stage III or IV or stage I or II if the tumor mass was greater than 10 cm or B symptoms were present). The complete response (CR) rate was 84% and the toxic death rate was 6%. Actuarial overall survival at 3 years was 67% and at 8 years 62%; the failure-free survival at 8 years was 52%. The follow-up for MACOP-B is 39 to 106 months (median 76) for living patients. A multivariate prognostic factor analysis for this group of patients identified age greater than 60 years. B symptoms, more than one extranodal site of disease, and more than three nodal sites of disease as the four significant prognostic variables. From June 1986, 108 patients were enrolled on a modification of MACOP-B called VACOP-B (etoposide/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin ). Their CR rate was 81%, and the toxic death rate was lower, at 3%. The 60% overall survival at 3 years is not statistically significantly different from that of MACOP-B. The incidence of moderate or severe mucositis and Cushingoid changes was much lower with VACOP-B. The MOPP/ABV (mechlorethamine/vincristine/procarbazine/prednisone- doxorubicin/bleomycin/vinblastine) hybrid chemotherapy regimen for advanced-stage Hodgkin's disease was standard therapy from April 1981 to June 1988 for untreated patients aged 16 to 65. Advanced stage was defined as stages IIB, IIIB, III2A, IVA, IVB, or stages IIA or IIIA with greater than four splenic nodules or a mediastinal mass greater than one third of the transthoracic diameter.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
2 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
17-23
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:1710485-Actuarial Analysis, pubmed-meshheading:1710485-Adolescent, pubmed-meshheading:1710485-Adult, pubmed-meshheading:1710485-Aged, pubmed-meshheading:1710485-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:1710485-Bleomycin, pubmed-meshheading:1710485-Cyclophosphamide, pubmed-meshheading:1710485-Doxorubicin, pubmed-meshheading:1710485-Drug Evaluation, pubmed-meshheading:1710485-Etoposide, pubmed-meshheading:1710485-Female, pubmed-meshheading:1710485-Hodgkin Disease, pubmed-meshheading:1710485-Humans, pubmed-meshheading:1710485-Leucovorin, pubmed-meshheading:1710485-Lymphoma, Large B-Cell, Diffuse, pubmed-meshheading:1710485-Male, pubmed-meshheading:1710485-Mechlorethamine, pubmed-meshheading:1710485-Methotrexate, pubmed-meshheading:1710485-Middle Aged, pubmed-meshheading:1710485-Mouth Mucosa, pubmed-meshheading:1710485-Prednisone, pubmed-meshheading:1710485-Procarbazine, pubmed-meshheading:1710485-Prognosis, pubmed-meshheading:1710485-Remission Induction, pubmed-meshheading:1710485-Stomatitis, pubmed-meshheading:1710485-Survival Rate, pubmed-meshheading:1710485-Vinblastine, pubmed-meshheading:1710485-Vincristine
pubmed:year
1991
pubmed:articleTitle
MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
pubmed:affiliation
British Columbia Cancer Agency, Vancouver, Canada.
pubmed:publicationType
Journal Article, Comparative Study